谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

1968P Study EV-103 Dose Escalation/cohort A (DE/A): 5y Follow-Up of First-Line (1L) Enfortumab Vedotin (EV) + Pembrolizumab (P) in Cisplatin (Cis)-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma (La/muc)

J.E. Rosenberg, D.P. Petrylak,T. Flaig,C.J. Hoimes, S. Gupta,P.H. O'Donnell,N. Mar,T. Friedlander,S.T. Tagawa,M.A. Bilen, J.R. Brown,R.R. McKay,J.R. Merchan, S. Srinivas, A. Shetty,B. Homet Moreno, G. Davis, H. Wirtz, Y. Zhu, M.I. Milowsky

Annals of Oncology（2024）

引用 0|浏览4
暂无评分
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要